The FDA has decided that the adverse events and deaths recorded in CTI BioPharma's pivotal program of the myelofibrosis drug pacritinib are so alarming that they've imposed a full clinical hold on the trial, halting dosing and persuading the biotech to yank its newly completed drug application. CTI is partnered with Baxalta ($BXLT) on the drug, which would compete with Novartis' ($NVS) Jakafi. More from FierceBiotech